Autres langues NewAmsterdam Pharma Company N.V. Börse Stuttgart

Actions

KH6

NL00150012L7

Recherche biotechnologique et médicale

Marché Fermé - Börse Stuttgart 21:56:17 18/09/2026			Varia. 5j.	Varia. 1 janv.
19,46 ^EUR	+2,10%		-0,82%	-33,79%

26/08	NewAmsterdam Pharma présente les données de son programme de développement de l'obicetrapib au congrès 2026 de la Société Européenne de Cardiologie	CI
14/08	NewAmsterdam Pharma Company N.V. annonce des changements au sein de sa direction	CI

Autres langues

04/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
03/09	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/09	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in September
26/08	NewAmsterdam Pharma Announces Upcoming Presentations at the European Society of Cardiology (ESC) Congress 2026
26/08	NewAmsterdam Pharma Presents Data From Obicetrapib Development Program At European Society Of Cardiology Congress 2026
14/08	Newamsterdam Pharma Company N.V. Announces Executive Changes
06/08	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/08	NewAmsterdam Pharma Company N.V. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
05/08	Earnings Flash (NAMS) NewAmsterdam Pharma Company N.V. Reports Q2 Revenue $3.7M, vs. FactSet Est of $1.9M
05/08	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
29/07	NewAmsterdam Pharma to Host Investor Day on August 5, 2026
27/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo and Evlarco
24/07	NewAmsterdam Pharma Says EMA Committee Recommends Approval of Cholesterol Treatments
24/07	Newamsterdam Pharma Company N.V. and Menarini Group Receives Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo (Obicetrapib Monotherapy) and Evlarco (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
24/07	NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
22/07	NewAmsterdam Pharma Company N.V. Announces Resignation of Douglas Kling from Chief Operating Officer, Effective August 14, 2026
08/07	Cambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in Pharma
02/07	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07	NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
01/07	NewAmsterdam Pharma Presents Data On Obicetrapib For Alzheimer?s Disease Prevention At AAIC 2026
30/06	NewAmsterdam Pharma's Obicetrapib Could Capture Market Share, RBC Capital Markets Says
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
03/06	NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
28/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
11/05	NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May